BioSpace News Archive

Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to raise approximately $10.0 million through the issuance of an aggregate 2,758,624 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,758,624 shares of common stock,

Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021 , after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5 p.m. EST . Participating in the call from Amgen

Dr. Buytaert-Hoefen will oversee direction and coordination of preclinical client consulting, specializing in the expansion and implementation of preclinical drug discovery and development plans from concept through preclinical studies including interactions with regulatory agencies.

Cardio Diagnostics, Inc, a biotechnology company making cardiovascular disease prevention and early detection more accessible, personalized and precise, announces the launch of its patent-pending flagship product, Epi+Gen CHD.

Chitrananda Abeygunawardana, Ph.D. will lead the development and execution of Venatorx’s global regulatory strategy for its clinical and pre-clinical anti-infectives programs for Venatorx Pharmaceuticals

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 17,530,488 shares of its common stock, at a price to the public of $2.05 per share

Calgary, Alberta--(Newsfile Corp. - January 28, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to announce that all follow-up visits of the subjects enrolled in the HS 12 -01 clinical trial will be completed by March 31, 2021.

12-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021.

Walgreens Boots Alliance, Inc. announced that its board of directors has declared a quarterly dividend of 46.75 cents per share, unchanged from the previous quarter and an increase of 2.2 percent from the year-ago quarter.

In an effort to expedite care for coronavirus disease 2019 patients upon hospital admission, a team at The Feinstein Institutes for Medical Research has developed a machine learning artificial intelligence powered clinical predictive tool that can accurately assess patients for the risk of respiratory failure within 48 hours.